Clinical trial
Impact of SGLT2 on Glucosuria in HNF1A-MODY
Name
H-21066984
Description
Maturity onset diabetes of the young (MODY) is a subtype of diabetes which is caused by mutations in specific genes leading to diabetes. The most common cause of MODY is due to mutations in the gene hepatocyte nuclear factor 1 alpha (HNF1A) and is consequently named HNF1A-MODY (or MODY3). HNF1A-MODY is associated with urinary excretion of glucose at lower blood glucose levels compared to other types of diabetes. Normally, glucose is reabsorbed by sodium-glucose cotransporter 2 (SGLT2), but SGLT2 is downregulated due to the mutation in HNF1A. Investigators aim to evaluate the impact of the decreased expression of SGLT2 on glucosuria in patients with HNF1A-MODY compared to patients with type 2 diabetes (T2D) using a single dose of an SGLT2 inhibitor during a glucose clamp experiment.
Trial arms
Trial start
2022-06-22
Estimated PCD
2023-06-14
Trial end
2023-06-14
Status
Completed
Treatment
Hyperglycaemic clamp
Three-hour, three-step glucose clamp with plasma glucose targets 10, 14 and 18 mmol/l (each one hour)
Arms:
HNF1A-MODY - Placebo, HNF1A-MODY - SGLT2 inhibition, Type 2 Diabetes - Placebo, Type 2 Diabetes - SGLT2 inhibition
Placebo
Placebo comparator to empagliflozin
Arms:
HNF1A-MODY - Placebo, Type 2 Diabetes - Placebo
Empagliflozin
Single-dose, 25 mg, two hours before clamp
Arms:
HNF1A-MODY - SGLT2 inhibition, Type 2 Diabetes - SGLT2 inhibition
Size
21
Primary endpoint
Urinary glucose excretion
Assesed during 3 hour hyperglycaemic clamp
Eligibility criteria
Inclusion Criteria:
* Age ≥18 years
* HNF1A-MODY verified by genetic testing (only patients with HNF1A-MODY)
* Type 2 diabetes diagnosis according to World Health Organization (only patients with type 2 diabetes)
* Treatment with diet and/or a glucose-lowering drug (only patients with HNF1A-MODY)
* Normal haemoglobin (males 8.3-10.5 mmol/l, females 7.3-9.5 mmol/l)
* Informed consent
Exclusion Criteria:
* Nephropathy (estimated GFR \<60 ml/min/1.73m2 and/or albuminuria)
* Known significant liver disease and/or plasma alanine aminotransferase (ALT) and/or plasma aspartate aminotransferase (AST) above 2 × normal values)
* Pregnancy or breastfeeding
* Treatment with SGLT2 inhibitor
* Fasting plasma glucose \> 10 mmol/l
* Family history of HNF1A-MODY (only patients with type 2 diabetes)
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['NA'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'CROSSOVER', 'primaryPurpose': 'BASIC_SCIENCE', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}}, 'enrollmentInfo': {'count': 21, 'type': 'ACTUAL'}}
Updated at
2023-07-27
1 organization
1 product
1 drug
3 indications
Organization
Steno Diabetes Center CopenhagenDrug
VarlilumabIndication
Maturity-Onset Diabetes of the YoungIndication
Type IIIIndication
Type 2 DiabetesProduct
Empagliflozin